NEW YORK (TheStreet) -- Shares of JPMorgan Chase & Co. (JPM) are higher by 2.47% to $62.90 in mid-afternoon trading on Friday, as the company announced its CEO James Dimon is cancer free, the Wall Street Journal reports.
Over the summer the financial services company's CEO announced he had throat cancer.
This week Dimon said he has completed a "thorough round of tests and scans," which came back clear, "showing no evidence of cancer in my body," Dimon said in a memo he shared with employees, the Journal added.
Must Read: Warren Buffett's 25 Favorite Stocks
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
"While the monitoring will continue for several years, the results are extremely positive and my prognosis remains excellent," Dimon added.
Separately, TheStreet Ratings team rates JPMORGAN CHASE & CO as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate JPMORGAN CHASE & CO (JPM) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, notable return on equity, increase in stock price during the past year and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow."